삼성서울병원

Ko En

Hematology-Oncology Yoon, Sang Eun M.D

Expertise
Lymphoma, multiple myeloma, Transplantation, CAR-T cell therapy,Hematopoietic stem cell transplantation, Amyloidosis
Treament Schedule 02 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
AM
PM
Treament Schedule 03 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
MON
31
AM
PM

Medical Education

2016~2020 Ph.D. in Medicine Medical school, EWHA Womans University, Seoul, Korea
2008~2012 Master of Science Medical school, EWHA Womans University, Seoul, Korea

Post-Graduate Training

Fellowship   2018~2019 Hematology/Oncology, Samsung Medical Center, Seoul, Korea
2017~2018 Hematology/Oncology, EWHA Womans university hospital, Seoul, Korea
Residency   2013~2017 Hematology/Oncology, EWHA Womans university hospital, Seoul, Korea
Internship   2012~2013 Hematology/Oncology, EWHA Womans university hospital, Seoul, Korea

Professional Appointments

2019~2024 Clinical Instructor Hematology/Oncology, Samsung Medical Center, Seoul, Korea
2024~Present Assistant Professor Hematology/Oncology, Samsung Medical Center, Seoul, Korea

Professional Memberships

2017~Present Member The Korean society of hematology
2013~Present Member The Korean association of internal medicine.

Selected Publications

  • ANN HEMATOL 2024 10.1007/s00277-024-06035-w Mutational characteristics of extranodal NK/T-cell lymphoma analyzed in relation to clinical prognostic indices Lee, J; Yoon, SE; Kim, SJ; Kim, WS; Cho, J
    View PubMed
  • SCI BULL 2024 10.1016/j.scib.2024.04.076 New insights on Epstein-Barr virus-induced lymphomagenesis Yoon, SE; Kim, WS
    View PubMed
  • EXP CELL RES 2024 10.1016/j.yexcr.2024.114248 Exosomal miR-155-5p drives ibrutinib resistance in B-cell lymphoma Park, B; Choi, ME; Ryu, KJ; Park, C; Choi, M; Yoon, SE; Kim, WS; Kim, HH; Hong, JY; Kim, SJ
    View PubMed
  • CANCER TREAT REV 2024 10.1016/j.ctrv.2024.102793 Peripheral T-cell lymphoma: From biology to practice to the future O'Connor, OA; Ma, H; Chan, JYS; Kim, SJ; Yoon, SE; Kim, WS
    View PubMed
  • BLOOD 2024 10.1182/blood.2023023419 CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis Kim, J; Cho, J; Lee, MH; Yoon, SE; Kim, WS; Kim, SJ
    View PubMed
  • ANN HEMATOL 2024 10.1007/s00277-024-05902-w Long-term survival outcomes of 'watch and wait' in patients with bronchus-associated lymphoid tissue lymphoma: a multicenter real-world data analysis in Korea Kwak, K; Yoo, KH; Choi, YS; Park, Y; Kim, BS; Yoon, SE; Kim, WS; Kang, KW; Kim, SJ
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.869 Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma Yoon, SE; Shin, SH; Nam, DK; Cho, J; Kim, WS; Kim, SJ
    View PubMed
  • ANN LAB MED 2024 10.3343/alm.2023.0388 Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies Kim, SJ; Yoon, SE; Kim, WS
    View PubMed
  • ANN HEMATOL 2024 10.1007/s00277-024-05739-3 Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma Yoon, SE; Cho, H; Berning, P; Cho, J; Kim, HY; Yoon, DH; Schmit, N; Kim, SJ; Kim, WS
    View PubMed
  • ACTA HAEMATOL-BASEL 2024 10.1159/000537962 Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell Lymphoma: Real-World Experience Choi, DH; Yoon, SE; Cho, JH; Kim, SJ; Kim, WS
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.1042 Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea Lee, JY; Kwon, JH; Hur, JY; Yi, JH; Lee, JH; Cho, H; Do, YR; Jo, JC; Kang, HJ; Koh, Y; Lee, WS; Lim, SN; Yoon, SE; Kim, SJ; Lee, JO
    View PubMed
  • HEMASPHERE 2024 10.1002/hem3.33 Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202) Cho, H; Kim, K; Yoon, SE; Jung, SH; Lee, JJ; Moon, JH; Cho, HJ; Lee, HS; Kang, KW; Kim, SY; Eom, HS; Mun, YC; Park, YH; Yoon, SS; Do, YR; Lee, WS; Min, CK; Yoon, DH
    View PubMed
  • ANN HEMATOL 2024 10.1007/s00277-024-05615-0 Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis Yi, JH; Park, SS; Min, CK; Eom, HS; Byun, JM; Koh, Y; Yoon, SS; Lee, JH; Jung, SH; Lee, JJ; Yoon, SE; Woo, SY; Kim, K
    View PubMed
  • FRONT ONCOL 2023 10.3389/fonc.2023.1194315 The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma Yoon, SE; Park, S; Cho, J; Ryu, KJ; Yandava, B; Lee, S; Kim, SJ; Kim, WS
    View PubMed
  • FRONT ONCOL 2023 10.3389/fonc.2023.1230629 Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation Kim, SJ; Jo, JC; Yoon, DH; Yang, DH; Yoon, SE; Lee, GW; Kong, JH; Park, Y; Kang, KW; Lee, HS; Oh, SY; Shin, HJ; Lee, WS; Choi, YS; Jeong, SH; Kim, MK; Kang, HJ; Yi, JH; Lim, SN; Yhim, HY; Do, YR; Yun, HJ; Eom, HS; Lee, MH; Suh, C; Kim, WS
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1658 Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis Kim, J; Cho, JHY; Yoon, SE; Kim, WS; Kim, SJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1535 Case Report of Erdheim-Chester Disease Successfully Treated with Pegylated Interferon: A Single-Center Experience Lim, Y; Yoon, SE; Cho, J; Kim, D; Jung, CW
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.6268 A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma Lee, H; Yoon, SE; Kim, SJ; Kim, WS; Cho, JH
    View PubMed
  • CANCER MANAG RES 2023 10.2147/CMAR.S407837 Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma Lee, YP; Yoon, SE; Cho, J; Ko, YH; Oh, D; Ahn, YC; Kim, WS; Kim, SJ
    View PubMed
  • BLOOD 2023 10.1182/blood.2022018831 The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma Yoon, SE; Kang, W; Choi, S; Park, Y; Chalita, M; Kim, H; Lee, JH; Hyun, DW; Ryu, KJ; Sung, H; Lee, JY; Bae, JW; Kim, WS; Kim, SJ
    View PubMed
  • ANN HEMATOL 2023 10.1007/s00277-023-05182-w Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma Jeon, Y; Yoon, SE; Cho, JH; Kim, SJ; Kim, WS
    View PubMed
  • FRONT IMMUNOL 2023 10.3389/fimmu.2023.1139980 Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections Yang, J; Won, G; Baek, JY; Lee, YH; Kim, H; Huh, K; Cho, SY; Kang, CI; Chung, DR; Peck, KR; Lee, KW; Park, JB; Yoon, SE; Kim, SJ; Kim, WS; Yim, MS; Kim, K; Hyeon, S; Kim, BC; Lee, YK; Ko, JH
    View PubMed
  • CL LYMPH MYELOM LEUK 2023 10.1016/j.clml.2022.10.010 Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea Kim, HR; Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K
    View PubMed
  • SEMIN HEMATOL 2023 10.1053/j.seminhematol.2022.10.002 Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management Tse, E; Fox, CP; Glover, A; Yoon, SE; Kim, WS; Kwong, YL
    View PubMed
  • FRONT ONCOL 2023 10.3389/fonc.2023.1109715 In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas Kim, JJ; Kim, HY; Choi, Z; Hwang, SY; Jeong, H; Choi, JR; Yoon, SE; Kim, WS; Kim, SH; Kim, HJ; Shin, SY; Lee, ST; Kim, SJ
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.34698 TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients Cho, J; Kim, E; Yoon, SE; Kim, SJ; Kim, WS
    View PubMed
  • FRONT ONCOL 2023 10.3389/fonc.2022.1071281 Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma Jeong, SY; Yoon, SE; Cho, D; Kang, ES; Cho, J; Kim, WS; Kim, SJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.015 A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum beta-2 Microglobulin to PINK Kang, S; Cho, H; Kim, S; Lee, K; Kang, EH; Park, JS; Lee, YS; Park, CS; Go, H; Huh, J; Ryu, JS; Lee, SW; Kim, SJ; Kim, WS; Yoon, SE; Ko, YH; Suh, C
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.017 Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas Kim, SJ; Kim, YJ; Yoon, SE; Ryu, KJ; Park, B; Park, D; Cho, D; Kim, HY; Cho, J; Ko, YH; Park, WY; Kim, WS
    View PubMed
  • VIRCHOWS ARCH 2023 10.1007/s00428-023-03493-x Comparison of histological and molecular features of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma Lee, J; Han, JH; Lee, CH; Park, HS; Min, SK; Lee, H; Cho, U; Yoon, SE; Kim, SJ; Kim, WS; Cho, JH
    View PubMed
  • INT J HEMATOL 2022 10.1007/s12185-022-03525-3 A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K
    View PubMed
  • BLOOD ADV 2022 10.1182/bloodadvances.2021006305 CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain Cho, J; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS
    View PubMed
  • CL LYMPH MYELOM LEUK 2022 10.1016/j.clml.2022.07.009 Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma Yoon, SE; Cho, J; Kim, YJ; Kim, SJ; Kim, WS
    View PubMed
  • BLOOD CANCER J 2022 10.1038/s41408-022-00755-w Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party Jung, SH; Kim, K; Yoon, SE; Moon, JH; Kim, D; Kim, HJ; Kim, MK; Ha Kim, K; Lee, HJ; Lee, JH; Kim, SH; Yoo, KH; Lee, JH; Lee, JJ
    View PubMed
  • J ONCOL 2022 10.1155/2022/2263217 Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis Lee, YP; Lee, MS; Yoon, SE; Cho, JH; Bang, YH; Shim, JH; Kim, WS; Kim, SJ
    View PubMed
  • ANN LAB MED 2022 10.3343/alm.2022.42.5.558 Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma Kim, HY; Yoo, IY; Lim, DJ; Kim, HJ; Kim, SH; Yoon, SE; Kim, SJ; Cho, D; Kim, K
    View PubMed
  • ANN HEMATOL 2022 10.1007/s00277-022-04805-y Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma Lee, YP; Yoon, SE; Cho, J; Ko, YH; Jo, H; Kim, SJ; Kim, WS
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.752 Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma Yoon, SE; Kim, YJ; Shim, JH; Park, D; Cho, J; Ko, YH; Park, WY; Mun, YC; Lee, KE; Cho, D; Kim, WS; Kim, SJ
    View PubMed
  • J CANCER 2022 10.7150/jca.69639 Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma Bang, YH; Shim, JH; Ryu, KJ; Kim, YJ; Choi, ME; Yoon, SE; Cho, J; Park, B; Park, WY; Kim, WS; Kim, SJ
    View PubMed
  • HEMATOL ONCOL 2022 10.1002/hon.2970 Promising clinical efficacy and acceptable safety profile of sequential P-GEMOX and radiotherapy for localized ENKTL Yoon, SE; Kim, WS
    View PubMed
  • BONE MARROW TRANSPL 2022 10.1038/s41409-022-01605-w Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis Yoon, SE; Jo, H; Kang, ES; Cho, D; Cho, J; Kim, WS; Kim, SJ
    View PubMed
  • J NEURO-ONCOL 2021 10.1007/s11060-021-03909-1 Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma Kim, N; Lim, DH; Yoon, SE; Kim, SJ; Kim, WS
    View PubMed
  • BLOOD CANCER J 2021 10.1038/s41408-021-00595-0 Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study Kang, D; Yoon, SE; Shin, D; Lee, J; Hong, YS; Lee, SK; Lee, JE; Park, YH; Ahn, JS; Guallar, E; Kim, WS; Lee, J; Kim, SJ; Cho, J
    View PubMed
  • BLOOD CANCER J 2021 10.1038/s41408-021-00577-2 Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT Cho, HJ; Jung, SH; Jo, JC; Lee, YJ; Yoon, SE; Park, SS; Kim, DY; Shin, HJ; Mun, YC; Yi, JH; Kim, HJ; Kim, DJ; Lee, HS; Bae, SH; Hong, CM; Jeong, SY; Min, JJ; Sohn, SK; Min, CK; Kim, K; Lee, JJ; Moon, JH
    View PubMed
  • ANN LAB MED 2021 10.3343/alm.2021.41.6.598 Aberrant Loss of Surface CD3 and TCR gamma delta Expression in Relapsed Hepatosplenic T-cell Lymphoma Lee, B; Lim, DJ; Heo, WY; Yoon, SE; Kim, HY; Kim, HJ; Kim, SH; Cho, D
    View PubMed
  • LEUKEMIA LYMPHOMA 2021 10.1080/10428194.2021.1971220 Prognostic significance of serum beta 2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified Kim, HD; Cho, H; Sohn, BS; Park, CS; Huh, J; Ryu, JS; Lee, SW; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS; Suh, C
    View PubMed
  • CANCER COMMUN 2021 10.1002/cac2.12212 Prognostic value of single-nucleotide polymorphisms for extranodal natural killer/T-cell lymphoma: the identification of risk factors in the molecular era Yoon, SE; Kim, WS
    View PubMed
  • CANCER MANAG RES 2021 10.2147/CMAR.S330308 Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma Lim, CH; Yoon, SE; Kim, WS; Lee, KH; Kim, SJ
    View PubMed
  • BMC CANCER 2021 10.1186/s12885-021-08695-7 Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing Cho, J; Yoon, SE; Kim, SJ; Ko, YH; Kim, WS
    View PubMed
  • ANN HEMATOL 2021 10.1007/s00277-021-04558-0 Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study Kim, WS; Oki, Y; Kim, SJ; Yoon, SE; Ardeshna, KM; Lin, Y; Ruan, J; Porcu, P; Brammer, JE; Jacobsen, ED; Yoon, DH; Suh, C; Suarez, F; Radford, J; Budde, LE; Kim, JS; Bachy, E; Lee, HJ; Bollard, CM; Jaccard, A; Kang, HJ; Inman, S; Murray, M; Combs, KE; Lee, DIY; Advani, R; Gunter, KC; Rooney, CM; Heslop, HE
    View PubMed
  • INT J HEMATOL 2021 10.1007/s12185-021-03179-7 Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia Lee, YP; Yoon, SE; Song, YQ; Kim, SJ; Yoon, DH; Chen, TY; Koh, YI; Kang, KW; Lee, HS; Wei, KTK; Lim, ST; Poon, M; Irawan, C; Zhao, WL; Do, YR; Lee, MH; Ng, SC; Lee, WS; Guo, Y; Zhang, HL; Kang, HJ; Yun, HJ; Kim, HJ; Lung, DTC; Kwak, JY; Han, JJ; Mun, YC; Oh, SY; Shim, H; Kwon, JH; Sohn, BS; Park, SK; Jo, JC; Ko, YH; Jun, Z; Kim, WS
    View PubMed
  • J NEURO-ONCOL 2021 10.1007/s11060-021-03815-6 Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy Kim, N; Lim, HD; Yoon, SE; Kim, SJ; Kim, WS
    View PubMed
  • J NEUROIMMUNOL 2021 10.1016/j.jneuroim.2021.577564 Increased proportion of CD20+T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report Lee1, JK; Kwon, S; Han, JH; Yoon, SE; Kim, BJ; Kang, ES
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.367 Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ
    View PubMed
  • CANCER MANAG RES 2021 10.2147/CMAR.S309092 Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma Lee1, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ
    View PubMed
  • EXP HEMATOL ONCOL 2021 10.1186/s40164-021-00224-3 Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas Yoon1, SE; Cho, J; Kim, YJ; Ko, YH; Park, WY; Kim, SJ; Kim, WS
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.628807 Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Lee1, B; Lee, H; Cho, J; Yoon, SE; Kim, SJ; Park, WY; Kim, WS; Ko, YH
    View PubMed
  • SCI REP-UK 2021 10.1038/s41598-021-85332-0 Metabolic activity of extranodal NK/T cell lymphoma on F-18-FDG PET/CT according to immune subtyping Lim1, CH; Yoon, SE; Kim, SJ; Cho, J; Ko, YH; Lee, KH; Kim, WS
    View PubMed
  • J CANCER 2021 10.7150/jca.55553 Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis Lee1, JY; Ryu, D; Lim, SW; Ryu, KJ; Choi, ME; Yoon, SE; Kim, K; Park, C; Kim, SJ
    View PubMed
  • J CANCER 2021 10.7150/jca.54434 Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months Yoon1, SE; Cho, J; Kim, WS; Kim, SJ
    View PubMed
  • J HEPATOL 2021 10.1016/j.jhep.2020.08.010 Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma Kim1, CG; Kim, C; Yoon, SE; Kim, KH; Choi, SJ; Kang, B; Kim, HR; Park, SH; Shin, EC; Kim, YY; Kim, DJ; Chung, HC; Chon, HJ; Choi, HJ; Lim, HY
    View PubMed
  • CANCERS 2020 10.3390/cancers12123548 Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma Ryu1, KJ; Lee, JY; Choi, ME; Yoon, SE; Cho, J; Ko, YH; Shim, JH; Kim, WS; Park, C; Kim, SJ
    View PubMed
  • BLOOD ADV 2020 10.1182/bloodadvances.2020002814 A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score Yhim1, HY; Eshet, Y; Metser, U; Lim, CH; Lajkosz, K; Isaev, K; Cooper, M; Prica, A; Kukreti, V; Bhella, S; Lang, N; Lee, KH; Xu, W; Hodgson, D; Tsang, R; Yoon, SE; Kim, SJ; Kim, WS; Crump, M; Kuruvilla, J; Kridel, R
    View PubMed
  • BLOOD 2020 10.1182/blood.2020005026 Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma Kim1, H; Jeong, H; Yamaguchi, M; Sohn, I; Yoon, SE; Byeon, S; Hur, JY; Koh, Y; Yoon, SS; Kim, EJ; Oguchi, M; Miyazaki, K; Taguchi, S; Yoon, DH; Cho, J; Ko, YH; Kim, SJ; Suzuki, R; Kim, WS
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-07317-y Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma Song1, GY; Jung, SH; Kim, K; Kim, SJ; Yoon, SE; Lee, HS; Kim, M; Ahn, SY; Ahn, JS; Yang, DH; Kim, HJ; Lee, JJ
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-68310-w Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era Song1, GY; Yoon, SE; Kim, SJ; Kim, JS; Koh, Y; Moon, JH; Oh, SY; Lee, HS; Shin, HJ; Do, YR; Lee, WS; Kim, DS; Park, Y; Yhim, HY; Yang, DH
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.396 Asian variant of intravascular large B-cell lymphoma a comparison of clinical features based on involvement of the central nervous system Yoon1, SE; Kim, WS; Kim, SJ
    View PubMed
  • ANN HEMATOL 2020 10.1007/s00277-020-04005-6 A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis Yoon1, SE; Kim, SJ; Yoon, KH; Koh, Y; Mun, YC; Do, YR; Choi, YS; Yang, DH; Kim, MK; Lee, GW; Suh, C; Ko, YH; Kim, WS
    View PubMed
  • ANN HEMATOL 2020 10.1007/s00277-020-04008-3 Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas Hur1, JY; Kim, YJ; Yoon, SE; Son, DS; Park, WY; Kim, SJ; Park, D; Kim, WS
    View PubMed
  • CYTOKINE 2020 10.1016/j.cyto.2020.155048 Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma Yi1, JH; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ
    View PubMed
  • ANN HEMATOL 2020 10.1007/s00277-020-04083-6 A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study Yoon1, SE; Eun, Y; Huh, K; Chung, CR; Yoo, IY; Cho, J; Cho, D; Ko, YH; Park, S; Kim, WS; Kim, SJ
    View PubMed
  • MODERN PATHOL 2020 10.1038/s41379-019-0392-8 Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression Cho1, J; Kim, SJ; Park, WY; Kim, J; Woo, J; Kim, G; Yoon, SE; Ko, YH; Kim, WS
    View PubMed
  • PSYCHO-ONCOL 2020 10.1002/pon.5265 Impact of fear of cancer recurrence on survival among lymphoma patients Kim1, SJ; Kang, D; Kim, IR; Yoon, SE; Kim, WS; Butow, PN; Guallar, E; Cho, J
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-6612-2 Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma Cho1, I; Lee, H; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • BMC UROL 2019 10.1186/s12894-019-0463-7 A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer Yoon1, SE; Kim, Y; Cho, J; Kang, M; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Lee, SJ; Park, SH
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed